This impression is loosely corroborated by our data in that patients with 3 types of gastrointestinal tract carcinomas presented significantly higher serum TGFBI levels with excess TGFBI derived from the tumor masses, whereas they were not elevated in patients with malignant tumors of other origins, such as bone, prostate, breast, and hematopoietic cells (Figure 1). This evidence concerns the gene TGFBI and cancer.